BUFDX
Price
$31.62
Change
-$0.01 (-0.03%)
Updated
Sep 20 closing price
VFINX
Price
$527.69
Change
-$1.02 (-0.19%)
Updated
Sep 20 closing price
Ad is loading...

BUFDX vs VFINX

Header iconBUFDX vs VFINX Comparison
Open Charts BUFDX vs VFINXBanner chart's image
Buffalo Growth & Income
Price$31.62
Change-$0.01 (-0.03%)
VolumeN/A
CapitalizationN/A
Vanguard 500 Index Investor
Price$527.69
Change-$1.02 (-0.19%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
BUFDX vs VFINX Comparison Chart
Loading...
VS
BUFDX vs. VFINX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BUFDX is a StrongBuy and VFINX is a Buy.

FUNDAMENTALS
Fundamentals
VFINX has more cash in the bank: 1.24T vs. BUFDX (164M). BUFDX pays higher dividends than VFINX: BUFDX (1.35) vs VFINX (1.24). BUFDX was incepted earlier than VFINX: BUFDX (12 years) vs VFINX (48 years). BUFDX (2.00) and VFINX (2.00) have comparable annual turnover. VFINX has a lower initial minimum investment than BUFDX: VFINX (0) vs BUFDX (2500). VFINX annual gain was more profitable for investors over the last year : 31.71 vs. BUFDX (27.68). VFINX (90.48) and BUFDX (86.38) have equivalent 5 years return.
BUFDXVFINXBUFDX / VFINX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence12 years48 years-
Gain YTD17.02219.94485%
Front LoadN/AN/A-
Min. Initial Investment25000-
Min. Initial Investment IRAN/AN/A-
Net Assets164M1.24T0%
Annual Yield % from dividends1.351.24109%
Returns for 1 year27.6831.7187%
Returns for 3 years31.8931.00103%
Returns for 5 years86.3890.4895%
Returns for 10 years159.42190.3584%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CTCX0.39N/A
+1.08%
Carmell Corp
OUT18.250.18
+1.00%
OUTFRONT Media
HITI2.11-0.03
-1.40%
High Tide
AMCR10.90-0.21
-1.89%
Amcor plc
FDMT11.90-1.60
-11.85%
4D Molecular Therapeutics